Reece Donna E
Department of Medical Oncology/Hematology, Princess Margaret Hospital, University Health Network, Toronto, Ontario, Canada M5G 2M9.
Blood Rev. 2007 Nov;21(6):301-14. doi: 10.1016/j.blre.2007.07.001. Epub 2007 Aug 29.
Many changes have been incorporated into the approach to multiple myeloma over the last few years, due to improvements in our understanding of the disease biology. New diagnostic and prognostic criteria from the International Myeloma Working Group have clarified the initial clinical approach to this disease. The prognostic impact of chromosomal abnormalities is now recognized, and the detection of specific abnormal cytogenetics is beginning to influence therapeutic decisions. The introduction of the novel agents thalidomide, bortezomib and lenalidomide has expanded treatment options at different points in the disease course; these agents are being evaluated in conjunction with conventional chemotherapy and stem cell transplantation. This report highlights some of the key recent findings in multiple myeloma, and describes areas for future research.
在过去几年里，由于我们对多发性骨髓瘤疾病生物学认识的提高，针对该病的治疗方法已融入了许多变化。国际骨髓瘤工作组制定的新诊断和预后标准明确了针对这种疾病的初始临床治疗方法。目前已认识到染色体异常对预后的影响，特定异常细胞遗传学检测开始影响治疗决策。新型药物沙利度胺、硼替佐米和来那度胺的引入在疾病进程的不同阶段扩大了治疗选择；这些药物正与传统化疗及干细胞移植联合进行评估。本报告重点介绍了多发性骨髓瘤近期的一些关键研究发现，并描述了未来的研究领域。
